Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study

被引：0
|
作者：
Zoghbi, Marianne [1 ]
Jabbour, Elias [1 ]
Haddad, Fadi [1 ]
Short, Nicholas James [1 ]
Senapati, Jayastu [1 ]
Macaron, Walid [1 ]
Nasnas, Cedric Christophe [1 ]
Nasr, Lewis Fady [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Wierda, William G. [1 ]
Borthakur, Gautam [1 ]
Bravo, Guillermo Montalban [1 ]
Ravandi, Farhad [1 ]
Garcia-Manero, Guillermo [1 ]
Kadia, Tapan M. [1 ]
Chien, Kelly Sharon [1 ]
Thankachan, Jennifer [1 ]
Garris, Rebecca [1 ]
Kantarjian, Hagop M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19039
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
    Kobayashi, Yukio
    Zimmerman, Zachary F.
    Oh, Iekuni
    Maeda, Yoshinobu
    Minami, Hironobu
    Miyamoto, Toshihiro
    Sakura, Toru
    Iida, Hiroatsu
    Chen, Yuqi
    Kiyoi, Hitoshi
    BLOOD, 2018, 132
  • [32] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
  • [33] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali
    Rodriguez, Vilmarie
    O'Brien, Maureen Megan
    McNeer, Jennifer Lynn
    Loh, Mignon L.
    Rheingold, Susan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
    Rafei, Hind
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Khoury, Joseph D.
    Wang, Sa A.
    Jorgensen, Jeffrey L.
    Yin, C. Cameron
    Khouri, Issa F.
    Kebriaei, Partow
    Jain, Nitin
    Takahashi, Koichi
    Dabaja, Bouthaina S.
    Verstovsek, Srdan
    Kadia, Tapan M.
    Paul, Shilpa
    Rausch, Caitlin R.
    Garcia-Manero, Guillermo
    Wierda, William G.
    DiNardo, Courtney D.
    Daver, Naval
    Montalban-Bravo, Guillermo
    Yilmaz, Musa
    Nasnas, Patrice
    Khouri, Rita
    Kwari, Monica
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    Konopleva, Marina
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [35] Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
    Short, Nicholas J.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Huang, Xuelin
    Jain, Nitin
    Sasaki, Koji
    Khouri, Rita
    Daver, Naval G.
    Pemmaraju, Naveen
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Alvarado, Yesid
    Konopleva, Marina Y.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Yilmaz, Musa E.
    Borthakur, Gautam M.
    Burger, Jan A.
    Kornblau, Steven M.
    Wierda, William G.
    DiNardo, Courtney D.
    Ferrajoli, Alessandra
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    Ward, Marygrace
    Huang, Binru
    Encarnacion, Corabelle
    Loiselle, Christopher
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2019, 134
  • [36] Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
    Short, Nicholas J.
    Kantarjian, Hagop
    Ravandi, Farhad
    Huang, Xuelin
    Jain, Nitin
    Kadia, Tapan M.
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Alvarado, Yesid
    Burger, Jan A.
    Daver, Naval
    Borthakur, Gautam
    DiNardo, Courtney D.
    Konopleva, Marina
    Pemmaraju, Naveen
    Garcia-Manero, Guillermo
    Wierda, William G.
    Kornblau, Steven M.
    Jacob, Jovitta
    Kwari, Monica
    Rausch, Caitlin R.
    Loiselle, Christopher
    Milton, Anna
    Rivera, Juan
    Garris, Rebecca
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2021, 138
  • [37] Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
    Short, Nicholas J.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Huang, Xuelin
    Jain, Nitin
    Kadia, Tapan M.
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Alvarado, Yesid
    Burger, Jan A.
    Daver, Naval
    Borthakur, Gautam
    DiNardo, Courtney D.
    Konopleva, Marina
    Pemmaraju, Naveen
    Garcia-Manero, Guillermo
    Wierda, William G.
    Kornblau, Steven M.
    Jacob, Jovitta
    Rostykus, Meagan
    Kwari, Monica
    Rausch, Caitlin R.
    Loiselle, Christopher
    Milton, Anna
    Rivera, Juan
    Garris, Rebecca
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [38] Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase
    Zoghbi, Marianne
    Jabbour, Elias
    Haddad, Fadi
    Short, Nicholas James
    Nasnas, Cedric Christophe
    Macaron, Walid
    Nasr, Lewis Fady
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Daver, Naval Guastad
    Chien, Kelly Sharon
    Valero, Yesid Alvarado
    Issa, Ghayas C.
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Thankachan, Jennifer
    Garris, Rebecca
    Ravandi, Farhad
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Ziegler, David S.
    Huynh, Van
    Burke, Michael J.
    Gore, Lia
    Locatelli, Franco
    O'Brien, Maureen M.
    Kim, Christopher
    Obreja, Mihaela
    Morris, Christopher L.
    Baruchel, Andre
    BLOOD, 2021, 138
  • [40] A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes
    Nasnas, Patrice
    Jabbour, Elias
    Short, Nicholas
    Ravandi, Farhad
    Huang, Xuelin
    Jain, Nitin
    Kadia, Tapan M.
    Alvarado, Yesid
    Burger, Jan A.
    Daver, Naval
    Borthakur, Gautam
    DiNardo, Courtney D.
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Wierda, William G.
    Jacob, Jovitta
    Deen, Wuliamatu
    Kwari, Monica
    Loiselle, Christopher
    Roy, Edith
    Milton, Anna
    Rivera, Juan
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 11679 - 11682
12345